{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:12:27Z","timestamp":1781503947071,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T00:00:00Z","timestamp":1345075200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2012.102","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T14:10:49Z","timestamp":1345126249000},"page":"e372-e372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim\/Bcl-2 complexes to activate Bax and Bak"],"prefix":"10.1038","volume":"3","author":[{"given":"T","family":"Melarangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Rockliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A G","family":"Bosanquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Oates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R","family":"Slupsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A R","family":"Pettitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,16]]},"reference":[{"key":"BFcddis2012102_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrc2764","volume":"10","author":"T Zenz","year":"2010","unstructured":"Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37\u201350.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2012102_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","volume":"82","author":"PD Thornton","year":"2003","unstructured":"Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82: 759\u2013765.","journal-title":"Ann Hematol"},{"key":"BFcddis2012102_CR3","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/leu.2008.214","volume":"22","author":"JE Castro","year":"2008","unstructured":"Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ . Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22: 2048\u20132053.","journal-title":"Leukemia"},{"key":"BFcddis2012102_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3324\/haematol.11903","volume":"93","author":"M Dungarwalla","year":"2008","unstructured":"Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E . High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008; 93: 475\u2013476.","journal-title":"Haematologica"},{"key":"BFcddis2012102_CR5","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/leu.2009.133","volume":"23","author":"JE Castro","year":"2009","unstructured":"Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009; 23: 1779\u20131789.","journal-title":"Leukemia"},{"key":"BFcddis2012102_CR6","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","volume":"30","author":"AR Pettitt","year":"2012","unstructured":"Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukaemia and deletion of TP53: Final results of the National Cancer Research Institute CLL206 Trial. J Clin Oncol 2012; 30: 1647\u20131655.","journal-title":"J Clin Oncol"},{"key":"BFcddis2012102_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mce.2008.10.001","volume":"300","author":"KL Gross","year":"2009","unstructured":"Gross KL, Lu NZ, Cidlowski JA . Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300: 7\u201316.","journal-title":"Mol Cell Endocrinol"},{"key":"BFcddis2012102_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2","volume":"68","author":"M Hala","year":"1996","unstructured":"Hala M, Hartmann BL, Bock G, Geley S, Kofler R . Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines. Int J Cancer 1996; 68: 663\u2013668.","journal-title":"Int J Cancer"},{"key":"BFcddis2012102_CR9","first-page":"5033","volume":"56","author":"S Geley","year":"1996","unstructured":"Geley S, Hartmann BL, Hala M, Strasser-Wozak EM, Kapelari K, Kofler R . Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression. Cancer Res 1996; 56: 5033\u20135038.","journal-title":"Cancer Res"},{"key":"BFcddis2012102_CR10","first-page":"1681","volume":"8","author":"S Greenstein","year":"2002","unstructured":"Greenstein S, Ghias K, Krett NL, Rosen ST . Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002; 8: 1681\u20131694.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"BFcddis2012102_CR11","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/sj.cdd.4401456","volume":"11","author":"S Schmidt","year":"2004","unstructured":"Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R . Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004; 11 (Suppl 1): S45\u2013S55.","journal-title":"Cell Death Differ"},{"key":"BFcddis2012102_CR12","doi-asserted-by":"publisher","first-page":"23861","DOI":"10.1074\/jbc.M301843200","volume":"278","author":"Z Wang","year":"2003","unstructured":"Wang Z, Malone MH, He H, McColl KS, Distelhorst CW . Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 2003; 278: 23861\u201323867.","journal-title":"J Biol Chem"},{"key":"BFcddis2012102_CR13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/sj.onc.1205205","volume":"21","author":"D Chauhan","year":"2002","unstructured":"Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002; 21: 1346\u20131358.","journal-title":"Oncogene"},{"key":"BFcddis2012102_CR14","first-page":"123","volume":"22","author":"F Casale","year":"2003","unstructured":"Casale F, Addeo R, D'Angelo V, Indolfi P, Poggi V, Morgera C et al. Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. Int J Oncol 2003; 22: 123\u2013128.","journal-title":"Int J Oncol"},{"key":"BFcddis2012102_CR15","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood.V90.9.3673","volume":"90","author":"J Chandra","year":"1997","unstructured":"Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M et al. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood 1997; 90: 3673\u20133681.","journal-title":"Blood"},{"key":"BFcddis2012102_CR16","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.V89.9.3378","volume":"89","author":"B Bellosillo","year":"1997","unstructured":"Bellosillo B, Dalmau M, Colomer D, Gil J . Involvement of CED-3\/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997; 89: 3378\u20133384.","journal-title":"Blood"},{"key":"BFcddis2012102_CR17","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2001-12-0327","volume":"100","author":"B Bellosillo","year":"2002","unstructured":"Bellosillo B, Villamor N, Lopez-Guillermo A, Marc\u00e9 S, Bosch F, Campo E et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002; 100: 1810\u20131816.","journal-title":"Blood"},{"key":"BFcddis2012102_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/sj.leu.2404483","volume":"21","author":"D Iglesias-Serret","year":"2007","unstructured":"Iglesias-Serret D, de Frias M, Santidrian AF, Coll-Mulet L, Cosialls AM, Barrag\u00e1n M et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007; 21: 281\u2013287.","journal-title":"Leukemia"},{"key":"BFcddis2012102_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1055\/s-0029-1211347","volume":"103","author":"M Soufi","year":"1995","unstructured":"Soufi M, Kaiser U, Schneider A, Beato M, Westphal HM . The DNA and steroid binding domains of the glucocorticoid receptor are not altered in mononuclear cells of treated CLL patients. Exp Clin Endocrinol Diabetes 1995; 103: 175\u2013183.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"BFcddis2012102_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1006\/bbrc.1998.9980","volume":"254","author":"H Shahidi","year":"1999","unstructured":"Shahidi H, Vottero A, Stratakis CA, Taymans SE, Karl M, Longui CA et al. Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. Biochem Biophys Res Commun 1999; 254: 559\u2013565.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis2012102_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1365-2141.2009.07741.x","volume":"146","author":"AG Bosanquet","year":"2009","unstructured":"Bosanquet AG, Richards SM, Wade R, Else M, Matutes E, Dyer MJ et al. Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. Br J Haematol 2009; 146: 384\u2013395.","journal-title":"Br J Haematol"},{"key":"BFcddis2012102_CR22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/362849a0","volume":"362","author":"AR Clarke","year":"1993","unstructured":"Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849\u2013852.","journal-title":"Nature"},{"key":"BFcddis2012102_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1365-2141.2004.05223.x","volume":"127","author":"A Carter","year":"2004","unstructured":"Carter A, Lin K, Sherrington PD, Pettitt AR . Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425\u2013428.","journal-title":"Br J Haematol"},{"key":"BFcddis2012102_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1600-0609.2004.00334.x","volume":"73","author":"A Aleskog","year":"2004","unstructured":"Aleskog A, Tobin G, Laurell A, Thunberg U, Lindhagen E, Roos G et al. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. Eur J Haematol 2004; 73: 407\u2013411.","journal-title":"Eur J Haematol"},{"key":"BFcddis2012102_CR25","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","volume":"111","author":"S Hewamana","year":"2008","unstructured":"Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008; 111: 4681\u20134689.","journal-title":"Blood"},{"key":"BFcddis2012102_CR26","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1096\/fj.06-7615rev","volume":"21","author":"M Neumann","year":"2007","unstructured":"Neumann M, Naumann M . Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J 2007; 21: 2642\u20132654.","journal-title":"FASEB J"},{"key":"BFcddis2012102_CR27","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1242\/jcs.00461","volume":"116","author":"G Nelson","year":"2003","unstructured":"Nelson G, Wilde GJ, Spiller DG, Kennedy SM, Ray DW, Sullivan E et al. NF-kappaB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci 2003; 116: 2495\u20132503.","journal-title":"J Cell Sci"},{"key":"BFcddis2012102_CR28","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1182\/blood-2005-04-1595","volume":"106","author":"M Erlacher","year":"2005","unstructured":"Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005; 106: 4131\u20134138.","journal-title":"Blood"},{"key":"BFcddis2012102_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2005.02.008","volume":"7","author":"TT Tan","year":"2005","unstructured":"Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005; 7: 227\u2013238.","journal-title":"Cancer Cell"},{"key":"BFcddis2012102_CR30","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1101\/gad.897601","volume":"15","author":"WX Zong","year":"2001","unstructured":"Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB . BH3-only proteins that bind prosurvival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15: 1481\u20131486.","journal-title":"Genes Dev"},{"key":"BFcddis2012102_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0092-8674(00)00167-7","volume":"103","author":"M Suzuki","year":"2000","unstructured":"Suzuki M, Youle RJ, Tjandra N . Structure of Bax: coregulation of dimer formation and intracellular localisation. Cell 2000; 103: 645\u2013654.","journal-title":"Cell"},{"key":"BFcddis2012102_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddis2012102_CR33","doi-asserted-by":"publisher","first-page":"10777","DOI":"10.1074\/jbc.273.17.10777","volume":"273","author":"Y-T Hsu","year":"1998","unstructured":"Hsu Y-T, Youle RJ . Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 1998; 273: 10777\u201310783.","journal-title":"J Biol Chem"},{"key":"BFcddis2012102_CR34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1083\/jcb.144.5.903","volume":"144","author":"GJ Griffiths","year":"1999","unstructured":"Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, Corfe BM et al. Cell damage-induced conformational changes of the proapoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999; 144: 903\u2013914.","journal-title":"J Cell Biol"},{"key":"BFcddis2012102_CR35","doi-asserted-by":"publisher","first-page":"44317","DOI":"10.1074\/jbc.M205273200","volume":"277","author":"T Panaretakis","year":"2002","unstructured":"Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D . Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002; 277: 44317\u201344326.","journal-title":"J Biol Chem"},{"key":"BFcddis2012102_CR36","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1182\/blood-2010-05-284968","volume":"116","author":"PS Bachmann","year":"2010","unstructured":"Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A et al. Epigenetic silencing of BIM in glucocorticoid poorresponsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116: 3013\u20133022.","journal-title":"Blood"},{"key":"BFcddis2012102_CR37","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1182\/blood-2010-02-268003","volume":"116","author":"JA Richter-Larrea","year":"2010","unstructured":"Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010; 116: 2531\u20132542.","journal-title":"Blood"},{"key":"BFcddis2012102_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183\u2013192.","journal-title":"Cancer Cell"},{"key":"BFcddis2012102_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Del Gaizo Moore","year":"2007","unstructured":"Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112\u2013121.","journal-title":"J Clin Invest"},{"key":"BFcddis2012102_CR40","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/leu.2009.151","volume":"23","author":"KD Mason","year":"2009","unstructured":"Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009; 23: 2034\u20132041.","journal-title":"Leukemia"},{"key":"BFcddis2012102_CR41","first-page":"4187","volume":"60","author":"AR Pettitt","year":"2000","unstructured":"Pettitt AR, Sherrington PD, Cawley JC . Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res 2000; 60: 4187\u20134193.","journal-title":"Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis2012102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis2012102","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2012102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:41:57Z","timestamp":1672962117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2012102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,16]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2012,8]]}},"alternative-id":["BFcddis2012102"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2012.102","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,16]]},"assertion":[{"value":"16 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}